Literature DB >> 6697645

Low-dose methotrexate kinetics in arthritis.

J Edelman, D F Biggs, F Jamali, A S Russell.   

Abstract

Twelve patients with either rheumatoid or psoriatic arthritis were injected with a 10-mg bolus dose of methotrexate (MTX) either intramuscularly (n = 6) or intravenously (n = 6) and the MTX concentration in their sera was determined by radioimmunoassay. MTX concentration--time data fitted triexponential equations. Doses injected intramuscularly were rapidly and completely absorbed. There were no significant intergroup differences in drug mean t 1/2, volume of distribution, and total body clearance. In nine patients serum MTX concentrations remained above the suggested critical level of 0.01 mumol throughout the 24-hr study irrespective of the route of administration, but MTX did not cumulate in the serum. We conclude that the behavior of low doses of MTX in patients with arthritis closely resembles the pattern in patients receiving intermediate and high doses for the treatment of neoplasia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6697645     DOI: 10.1038/clpt.1984.47

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine.

Authors:  G Nesher; T L Moore; R W Dorner
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

2.  A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

Authors:  F Bressolle; C Bologna; L Edno; J C Bernard; R Gomeni; J Sany; B Combe
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Methotrexate therapy in rheumatoid arthritis. Current status.

Authors:  W S Wilke; A H Mackenzie
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

5.  Use of methotrexate in older patients. A risk-benefit assessment.

Authors:  S E Tett; E J Triggs
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

6.  The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.

Authors:  P Seideman; O Beck; S Eksborg; M Wennberg
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

8.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 9.  Slow-acting antirheumatic drugs. Drug interactions of clinical significance.

Authors:  R A Munro; R D Sturrock
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

10.  Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics.

Authors:  F Albertioni; B Flatø; P Seideman; O Beck; O Vinje; C Peterson; S Eksborg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.